Medline’s Blockbuster IPO Signals a Comeback for Public Offerings
A recent development in the financial world has sparked renewed optimism about the state of the initial public offering (IPO) market. Medline, a medical supplier, has made headlines with its massive IPO, raising nearly $6.3 billion and experiencing a 41% stock jump after its debut on Nasdaq. This significant event has led experts to predict a strong year for stock offerings, with the total amount raised by traditional U.S. IPOs in 2025 already surpassing the $31.7 billion raised in 2024.
Medline CEO Jim Boyle (R) celebrates after ringing the opening bell at Nasdaq Marketsite headquarters on Dec. 17, 2025. Photo by Michael M. Santiago/Getty Images
IPO Market Resilience and Future Prospects
Despite facing challenges such as the longest-ever U.S. government shutdown and shifting tariff policies, the IPO market has demonstrated remarkable resilience in 2025. According to Sam Kerr, head of global ECM at Mergermarket, “The huge demand for Medline’s IPO in the last week is a strong market to end the year with.” This optimism is further supported by the expected listings of several high-profile companies in 2026, including Elon Musk’s SpaceX and A.I. darling Anthropic.
A recent report from XTB suggests that an IPO from either SpaceX or Anthropic “would likely lead to an A.I. frenzy” and mark “the stock market event of the year.” Additionally, international listings from companies such as Chinese fast-fashion giant Shein and Australian software firm Canva are also being closely watched by investors.
Global IPO Activity and Market Trends
Global IPO activity has experienced a significant rebound in 2025, with $151 billion raised so far, according to Dealogic. This nears the record $154 billion raised in 2022 and marks the strongest year since. The confidence in the IPO market is further boosted by a recent pullback in Big Tech stocks, which could increase demand for listings outside the U.S., particularly in Europe.
As Sam Kerr notes, “This could increase demand for listing outside the U.S., like Europe, where there are several investment themes playing to investor demand.” The expected listings of French-German tank maker KNDS and Czech defense manufacturer CGS are particularly promising, with defense being a notable area of interest.
In conclusion, Medline’s blockbuster IPO has signaled a comeback for public offerings, with the IPO market demonstrating resilience and optimism for the future. As the year draws to a close, market participants are confident of an even better 2026, with several high-profile listings on the horizon. For more information, visit Here
Image Source: observer.com
